Literature DB >> 8349808

Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses.

C A Jaffe1, R D Friberg, A L Barkan.   

Abstract

To study the potential involvement of growth hormone-releasing hormone (GHRH) in the generation of growth hormone (GH) pulses in humans we have used a competitive antagonist to the GHRH receptor, (N-Ac-Tyr1,D-Arg2)GHRH(1-29)NH2(GHRH-Ant). Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h. Integrated total and pulsatile GH secretion were suppressed during GHRH-Ant treatment by 40 +/- 6 (SE) % and 75 +/- 5%, respectively. GHRH-Ant suppressed maximum (7.6 +/- 2.2 vs 1.8 +/- 0.5 micrograms/liter; P < 0.001) and mean (3.3 +/- 1.0 vs 1.1 +/- 0.2 micrograms/liter; P = 0.02) GH pulse amplitudes. There was no change in integrated nonpulsatile GH levels, pulse frequency, or interpulse GH concentration. GHRH-Ant 400 micrograms/kg also suppressed the GH responses to intravenous boluses of GHRH 0.33 micrograms/kg given 1, 6, 12, and 24 h later by 95, 81, 59, and 4%, respectively. In five healthy men, the responses to 10-fold larger GHRH boluses (3.3 micrograms/kg) were suppressed by 82 and 0%, 1 and 6 h after GHRH-Ant 400 micrograms/kg, respectively. These studies provide the first direct evidence that endogenous GHRH participates in the generation of spontaneous GH pulses in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349808      PMCID: PMC294903          DOI: 10.1172/JCI116639

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection.

Authors:  J D Veldhuis; M L Johnson
Journal:  Am J Physiol       Date:  1986-04

2.  Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH.

Authors:  M L Vance; D L Kaiser; J Rivier; W Vale; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1986-03       Impact factor: 5.958

3.  Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells.

Authors:  J Fukata; D J Diamond; J B Martin
Journal:  Endocrinology       Date:  1985-08       Impact factor: 4.736

4.  Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man.

Authors:  M L Vance; J L Borges; D L Kaiser; W S Evans; R Furlanetto; J L Thominet; L A Frohman; A D Rogol; R M MacLeod; S Bloom
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

5.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

6.  The interaction of human pancreatic growth hormone releasing factor 1-44 with somatostatin in vivo in normal man.

Authors:  R R Davies; S J Turner; H Orskov; D G Johnston
Journal:  Clin Endocrinol (Oxf)       Date:  1985-09       Impact factor: 3.478

7.  Plasma growth hormone (GH) and somatomedin C response to continuous growth hormone-releasing factor (GRF) infusion in patients with GH deficiency.

Authors:  N Hizuka; K Takano; K Shizume; I Tanaka; N Honda; N C Ling
Journal:  Acta Endocrinol (Copenh)       Date:  1985-09

8.  Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat.

Authors:  P M Plotsky; W Vale
Journal:  Science       Date:  1985-10-25       Impact factor: 47.728

9.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.

Authors:  C Y Bowers; F A Momany; G A Reynolds; A Hong
Journal:  Endocrinology       Date:  1984-05       Impact factor: 4.736

10.  Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.

Authors:  P Robberecht; D H Coy; M Waelbroeck; M L Heiman; P de Neef; J C Camus; J Christophe
Journal:  Endocrinology       Date:  1985-11       Impact factor: 4.736

View more
  15 in total

Review 1.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

2.  Relationship between hypophyseal portal GHRH and somatostatin and peripheral GH levels in the conscious sheep.

Authors:  M Cataldi; E Magnan; V Guillaume; A Dutour; B Conte-Devolx; G Lombardi; C Oliver
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

Review 3.  Pharmacotherapy or surgery as primary treatment for acromegaly?

Authors:  D Ferone; A Colao; A J van der Lely; S W Lamberts
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

Review 4.  Growth hormone pulsatility in acromegaly following radiotherapy.

Authors:  S R Peacey; S M Shalet
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

5.  Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release.

Authors:  M L Hartman; S M Pincus; M L Johnson; D H Matthews; L M Faunt; M L Vance; M O Thorner; J D Veldhuis
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

Review 6.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

Review 7.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

8.  Role of growth hormone in regulating lipolysis, proteolysis, and hepatic glucose production during fasting.

Authors:  Alla A Sakharova; Jeffrey F Horowitz; Sowmya Surya; Naila Goldenberg; Matthew P Harber; Kathy Symons; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

9.  Regulatory mechanisms of growth hormone secretion are sexually dimorphic.

Authors:  C A Jaffe; B Ocampo-Lim; W Guo; K Krueger; I Sugahara; R DeMott-Friberg; M Bermann; A L Barkan
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

10.  Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin.

Authors:  M Bermann; C A Jaffe; W Tsai; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.